Progesterone Receptor Membrane Component 1 Modulates Human Cytochrome P450 Activities in an Isoform-Dependent Manner

被引:29
作者
Oda, Shingo [1 ]
Nakajima, Miki [1 ]
Toyoda, Yasuyuki [1 ]
Fukami, Tatsuki [1 ]
Yokoi, Tsuyoshi [1 ]
机构
[1] Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan
关键词
INNER ZONE ANTIGEN; HUMAN-LIVER; PGRMC1; P450; EXPRESSION; MICROSOMES; OXIDATION; BINDING; MOUSE; 3A4;
D O I
10.1124/dmd.111.040907
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochromes P450 (P450s) catalyze the metabolism of a wide spectrum of compounds. Recently, progesterone receptor membrane component 1 (PGRMC1), which shares a key structural motif with cytochrome b(5), has been reported to bind to sterol-or steroid-synthesizing P450s, enhancing their activities. In this study, we investigated whether PGRMC1 affects human drug-metabolizing P450 activities. Using coexpression systems for PGRMC1 and P450s (CYP3A4, CYP2C9, or CYP2E1) in HepG2 cells, we found that PGRMC1 decreased the V-max values and increased the K-m values of the CYP3A4 activities, and it decreased the V-max values but did not affect the K-m values of the CYP2C9 activities. In contrast, PGRMC1 hardly affected the CYP2E1 activities. These results suggest that PGRMC1 negatively modulates the drug-metabolizing activities of P450, although it was isoform but not substrate de-pendent. It is worth noting that coimmunoprecipitation analysis using coexpression systems for FLAG-PGRMC1 and Myc-P450s in human embryonic kidney 293 cells revealed that PGRMC1 interacts with all three P450s, although the affinity seemed to vary. In 29 human liver microsomes (HLMs), there was a 5-fold variability in the PGRMC1 protein levels. By the correlation analyses using the P450 activities and the PGRMC1 levels, we could neither observe the contribution of PGRMC1 to the P450 activities in HLMs nor that of the NADPH-cytochrome P450 reductase or cytochrome b(5). In conclusion, in contrast to sterol-or steroid-synthesizing P450s, we found that PGRMC1 negatively modulates the human drug-metabolizing activities of P450 through direct interaction. Further studies are needed to determine the clinical significance of PGRMC1 in the pharmacokinetics of drugs.
引用
收藏
页码:2057 / 2065
页数:9
相关论文
共 30 条
  • [1] Progesterone receptor membrane component 1: An integrative review
    Cahill, Michael A.
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2007, 105 (1-5) : 16 - 36
  • [2] Overexpression of the cytochrome P450 activator Hr6 (heme-1 domain protein/hman progesterone receptor) in tumors
    Crudden, G
    Loesel, R
    Craven, RJ
    [J]. TUMOR BIOLOGY, 2005, 26 (03) : 142 - 146
  • [3] A helping hand for cytochrome P450 enzymes
    DeBose-Boyd, Russell A.
    [J]. CELL METABOLISM, 2007, 5 (02) : 81 - 83
  • [4] Spectroscopic and biochemical characterization of hemne binding to yeast Dap1p and mouse PGRMC1p
    Ghosh, K
    Thompson, AM
    Goldbeck, RA
    Shi, XL
    Whitman, S
    Oh, E
    Zhu, ZW
    Vulpe, C
    Holman, TR
    [J]. BIOCHEMISTRY, 2005, 44 (50) : 16729 - 16736
  • [5] Rate-limiting steps in cytochrome P450 catalysis
    Guengerich, FP
    [J]. BIOLOGICAL CHEMISTRY, 2002, 383 (10) : 1553 - 1564
  • [6] An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and γ-glutamylcysteine synthetase knockdown cells
    Hosomi, Hiroko
    Akai, Sho
    Minami, Keiichi
    Yoshikawa, Yukitaka
    Fukami, Tatsuki
    Nakajima, Miki
    Yokoi, Tsuyoshi
    [J]. TOXICOLOGY IN VITRO, 2010, 24 (03) : 1032 - 1038
  • [7] Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes
    Hughes, Adam L.
    Powell, David W.
    Bard, Martin
    Eckstein, James
    Barbuch, Robert
    Link, Andrew J.
    Espenshade, Peter J.
    [J]. CELL METABOLISM, 2007, 5 (02) : 143 - 149
  • [8] CYP2C9-Mediated Metabolic Activation of Losartan Detected by a Highly Sensitive Cell-Based Screening Assay
    Iwamura, Atsushi
    Fukami, Tatsuki
    Hosomi, Hiroko
    Nakajima, Miki
    Yokoi, Tsuyoshi
    [J]. DRUG METABOLISM AND DISPOSITION, 2011, 39 (05) : 838 - 846
  • [9] Expression of human cytochromes P450 in chimeric mice with humanized liver
    Katoh, M
    Matsui, T
    Nakajima, M
    Tateno, C
    Kataoka, M
    Soeno, Y
    Horie, T
    Iwasaki, K
    Yoshizato, K
    Yokoi, T
    [J]. DRUG METABOLISM AND DISPOSITION, 2004, 32 (12) : 1402 - 1410
  • [10] KRONBACH T, 1989, MOL PHARMACOL, V36, P89